Phase III clinical trial Oligometastatic and Oligorecurrent PROstate Cancer: enhancing patients’ selection by new ImagiNG biomarkers - PROvING

AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA0 个研究点目标入组 246 人开始时间: 2020年10月21日最近更新: 2020年12月7日

适应症

试验速览

暂无简介。

•Related to PCa:
•1. Histologically documented castration resistant PCa treated with radical prostatectomy or loco-regional EBRT.
•2. BCR PCa demonstrated by two consecutive PSA determinations
•3. Life expectancy of more than 6 months.
•Related to the patient:
•4. Male patients aged >18 years without upper age limit.
•5. Ability to understand and willingness to sign a written informed consent document.
•6. Written informed consent obtained according to international guidelines and local laws.
•7. Compliant to the study procedures, based on the Investigator point of view.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 61
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 185

•Related to the PCa
•1. Other malignancies
•Related to the patient:
•1. Patient not willing to sign a written informed consent document.
•2. Patient with severe chronic renal disease (according to the KDOQI/CTCAE eGFR or CrCl< 15 ml/min/1.73m2).

发起方